F-1/A: Mainz Biomed N.V. Files Amendment for $8 Million Securities Offering

Mainz Biomed N.V. has filed an amendment to its registration statement for a proposed offering of up to $8 million in ordinary and pre-funded units, including warrants.

Summary

• Mainz Biomed N.V. is proposing a best-efforts offering of up to 1,147,776 ordinary units, each including one ordinary share, a Class A warrant, and a Class B warrant.
• The company is also offering pre-funded units to purchasers who would exceed 4.99% ownership, each including a pre-funded warrant, a Class A warrant, and a Class B warrant.
• The assumed offering price is $6.97 per ordinary unit, based on the closing price of the ordinary shares on December 6, 2024.
• Pre-funded units will be priced at $0.0001 less than the ordinary unit price.
• The offering includes up to 3,443,328 ordinary shares underlying the warrants.
• The Class A warrants and Class B warrants have an exercise price of $6.97 and are exercisable for one ordinary share.
• The Class A warrants expire five years from issuance, while the Class B warrants expire one year from issuance or 30 days after the eAArly Detect 2 study results are released.
• The company expects net proceeds of approximately $7,125,000 from the offering, after deducting fees and expenses.
• The funds will be used for the eAArly Detect 2 study, development of the next-generation screening product, commercial expansion of ColoAlert, repayment of convertible debt, and general corporate purposes.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is pursuing growth opportunities and has promising technology, it faces significant financial challenges and risks, including going concern issues and Nasdaq delisting concerns. The sentiment is neutral to slightly negative due to the financial uncertainties.

Positives

• The offering will provide capital for the eAArly Detect 2 study, which is a key clinical trial for the company.
• The funds will support the development of the next-generation screening product, which is a key growth driver for the company.
• The offering will enable the commercial expansion of ColoAlert, which is the company's current flagship product.
• The company will use a portion of the proceeds to repay convertible debt, which will improve its financial position.

Negatives

• The offering is on a best-efforts basis, meaning there is no guarantee that the company will raise the full $8 million.
• The market price of the company's ordinary shares may be volatile and may fluctuate in a way that is disproportionate to its operating performance.
• Investors will experience immediate and substantial dilution as a result of the offering.
• There is no public market for the pre-funded warrants, Class A warrants, or Class B warrants being offered.

Risks

• The company is an early revenue stage company and has incurred operating losses since inception.
• The company's financial statements include an explanatory paragraph from its auditor indicating substantial doubt about its ability to continue as a going concern.
• The company's success depends heavily on its ColoAlert screening tests.
• The company may not succeed in establishing, maintaining, and strengthening its brands.
• The company may face technology transfer challenges and expenses in adding new tests to its portfolio.
• The company may depend on future collaborations to develop and commercialize its diagnostic test candidates.
• The company may be subject to significant fines and penalties if it or its partners fail to comply with laws and regulations.
• The company has been notified by Nasdaq that it is not in compliance with certain standards which Nasdaq requires listed companies meet for their respective securities to continue to be listed and traded on its exchange.
• The company enacted a reverse stock split in an effort to regain compliance with the Minimum Bid Price Requirement, and the public market may react negatively to this reverse stock split.

Future Outlook

The company intends to use the net proceeds from this offering for the eAArly Detect 2 study, the development of its next-generation screening product, the commercial expansion of its ColoAlert product, repayment of convertible debt, and for general corporate purposes.

Management Comments

• The company believes that cost reductions will position the business for success in 2025 and beyond.
• The company is progressively extending its operations to additional European markets that are accustomed to personal health expenditures.
• The company is not currently seeking statutory reimbursement for ColoAlert, as it believes its next-generation test is more attuned to the stringent criteria set by German regulatory and reimbursement agencies.

Industry Context

The document highlights the significant market opportunity in colorectal cancer diagnostics, with the annual market expected to surpass $30 billion by 2032. The company is positioning itself to capitalize on this growing market with its ColoAlert test and next-generation mRNA-based screening test. The document also notes the rising prevalence of CRC in younger populations, which is expected to drive demand for early screening methods.

Comparison to Industry Standards

• The document compares the sensitivity and specificity of Mainz Biomed's next-generation mRNA CRC screening test to competing products, including Cologuard, Exact Sciences, and Fecal Immunochemical Tests (FIT).
• The company's pooled study data shows a sensitivity of 92% for CRC and 82% for advanced adenomas (AAs), with a specificity of 90% for both.
• Cologuard, a competing product, has a sensitivity of 92% for CRC and 42% for AAs, with a specificity of 87%.
• FIT tests have a sensitivity of 24% for CRC and 10% for AAs, with a specificity of 95%.
• The company's next-generation test demonstrates higher sensitivity for AAs compared to Cologuard and FIT tests, suggesting a potential advantage in detecting precancerous lesions.

Legal Proceedings

• Mainz filed a lawsuit against an investment bank in connection with a right of first refusal granted in 2021.
• The investment bank initiated arbitration proceedings against Mainz, which have been stayed.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may be affected by the company's restructuring and cost reduction measures.
• Customers may benefit from the development of new and improved diagnostic tests.
• Creditors may be impacted by the company's repayment of convertible debt.

Next Steps

• The company will conduct the eAArly Detect 2 clinical study in the U.S. in 2025.
• The company will continue the development of its next-generation screening product.
• The company will focus on the commercial expansion of its ColoAlert product in Europe.
• The company will make monthly payments on its convertible debenture starting January 31, 2025.

Key Dates

Keywords

Colorectal Cancer, Screening, Diagnostics, Warrants, mRNA, ColoAlert, PancAlert, Clinical Trials, Reverse Stock Split, Capital Raise